🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
6.65
+0.95 (16.67%)
Nov 18, 2026, 4:00 PM EST - Market closed

Akari Therapeutics, Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.49.289.6611.3613.538.08
Research & Development
6.732.826.985.459.569.13
Operating Expenses
16.1412.116.6516.8123.0917.21
Operating Income
-16.14-12.1-16.65-16.81-23.09-17.21
Interest Expense
-0.95-0.95-0.24---
Interest & Investment Income
-00.010.080.050.01
Currency Exchange Gain (Loss)
-0.41-0.440.010.140.45-0.19
Other Non Operating Income (Expenses)
3.53.532.086.584.84-0.03
EBT Excluding Unusual Items
-14-9.96-14.8-10.01-17.75-17.42
Merger & Restructuring Charges
---5---
Impairment of Goodwill
-8.43-----
Asset Writedown
-3.7-5.18----
Other Unusual Items
-4.05-3.16----
Pretax Income
-30.18-18.3-19.79-10.01-17.75-17.42
Income Tax Expense
-0.77-1----
Net Income
-29.4-17.3-19.79-10.01-17.75-17.42
Net Income to Common
-29.4-17.3-19.79-10.01-17.75-17.42
Net Income Growth
------
Shares Outstanding (Basic)
210000
Shares Outstanding (Diluted)
210000
Shares Change
177.53%181.85%144.03%56.79%45.46%35.87%
EPS (Basic)
-15.29-20.55-66.28-81.79-227.41-324.77
EPS (Diluted)
-15.29-20.55-66.28-81.79-227.41-324.77
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-12.86-10.57-12.55-16.43-21.5-18.85
Free Cash Flow Per Share
-6.69-12.56-42.04-134.29-275.54-351.28
EBITDA
--12.08-16.63-16.8-23.08-17.21
D&A For EBITDA
-0.010.01000
EBIT
-16.14-12.1-16.65-16.81-23.09-17.21
SEC Filings: 10-K · 10-Q